The role of NOX inhibitors in neurodegenerative diseases

Sumit Barua, Jong Youl Kim, Midori A. Yenari, Jong Eun Lee

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Oxidative stress is a key player in both chronic and acute brain disease due to the higher metabolic demand of the brain. Among the producers of free radicals, NADPH-oxidase (NOX) is a major contributor to oxidative stress in neurological disorders. In the brain, the superoxide produced by NOX is mainly found in leukocytes. However, recent studies have reported that it can be found in several other cell types. NOX has been reported to regulate neuronal signaling, memory processing, and central cardiovascular homeostasis. However, overproduction of NOX can contribute to neurotoxicity, CNS degeneration, and cardiovascular disorders. Regarding the above functions, NOX has been shown to play a crucial role in chronic CNS diseases like Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and in acute CNS disorders such as stroke, spinal cord injury, traumatic brain injury (TBI), and related cerebrovascular diseases. NOX is a multi-subunit complex consisting of two membrane-associated and four cytosolic subunits. Thus, in recent years, inhibition of NOX activity has drawn a great deal of attention from researchers in the field of treating chronic and acute CNS disorders and preventing secondary complications. Mounting evidence has shown that NOX inhibition is neuroprotective and that inhibiting NOX in circulating immune cells can improve neurological disease conditions. This review summarizes recent studies on the therapeutic effects and pharmacological strategies regarding NOX inhibitors in chronic and acute brain diseases and focuses on the hurdles that should be overcome before their clinical implementation.

Original languageEnglish
Pages (from-to)59-69
Number of pages11
JournalIBRO Reports
Volume7
DOIs
Publication statusPublished - 2019 Dec

Fingerprint

NADPH Oxidase
Neurodegenerative Diseases
Brain Diseases
Acute Disease
Oxidative Stress
Cerebrovascular Disorders
Central Nervous System Diseases
Huntington Disease
Amyotrophic Lateral Sclerosis
Brain
Therapeutic Uses
Nervous System Diseases
Spinal Cord Injuries
Superoxides
Multiple Sclerosis
Free Radicals
Parkinson Disease
Alzheimer Disease
Leukocytes
Homeostasis

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

Barua, Sumit ; Kim, Jong Youl ; Yenari, Midori A. ; Lee, Jong Eun. / The role of NOX inhibitors in neurodegenerative diseases. In: IBRO Reports. 2019 ; Vol. 7. pp. 59-69.
@article{9ffec2901ad94d72b622f2d1ab170f3f,
title = "The role of NOX inhibitors in neurodegenerative diseases",
abstract = "Oxidative stress is a key player in both chronic and acute brain disease due to the higher metabolic demand of the brain. Among the producers of free radicals, NADPH-oxidase (NOX) is a major contributor to oxidative stress in neurological disorders. In the brain, the superoxide produced by NOX is mainly found in leukocytes. However, recent studies have reported that it can be found in several other cell types. NOX has been reported to regulate neuronal signaling, memory processing, and central cardiovascular homeostasis. However, overproduction of NOX can contribute to neurotoxicity, CNS degeneration, and cardiovascular disorders. Regarding the above functions, NOX has been shown to play a crucial role in chronic CNS diseases like Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and in acute CNS disorders such as stroke, spinal cord injury, traumatic brain injury (TBI), and related cerebrovascular diseases. NOX is a multi-subunit complex consisting of two membrane-associated and four cytosolic subunits. Thus, in recent years, inhibition of NOX activity has drawn a great deal of attention from researchers in the field of treating chronic and acute CNS disorders and preventing secondary complications. Mounting evidence has shown that NOX inhibition is neuroprotective and that inhibiting NOX in circulating immune cells can improve neurological disease conditions. This review summarizes recent studies on the therapeutic effects and pharmacological strategies regarding NOX inhibitors in chronic and acute brain diseases and focuses on the hurdles that should be overcome before their clinical implementation.",
author = "Sumit Barua and Kim, {Jong Youl} and Yenari, {Midori A.} and Lee, {Jong Eun}",
year = "2019",
month = "12",
doi = "10.1016/j.ibror.2019.07.1721",
language = "English",
volume = "7",
pages = "59--69",
journal = "IBRO Reports",
issn = "2451-8301",
publisher = "Elsevier Limited",

}

The role of NOX inhibitors in neurodegenerative diseases. / Barua, Sumit; Kim, Jong Youl; Yenari, Midori A.; Lee, Jong Eun.

In: IBRO Reports, Vol. 7, 12.2019, p. 59-69.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The role of NOX inhibitors in neurodegenerative diseases

AU - Barua, Sumit

AU - Kim, Jong Youl

AU - Yenari, Midori A.

AU - Lee, Jong Eun

PY - 2019/12

Y1 - 2019/12

N2 - Oxidative stress is a key player in both chronic and acute brain disease due to the higher metabolic demand of the brain. Among the producers of free radicals, NADPH-oxidase (NOX) is a major contributor to oxidative stress in neurological disorders. In the brain, the superoxide produced by NOX is mainly found in leukocytes. However, recent studies have reported that it can be found in several other cell types. NOX has been reported to regulate neuronal signaling, memory processing, and central cardiovascular homeostasis. However, overproduction of NOX can contribute to neurotoxicity, CNS degeneration, and cardiovascular disorders. Regarding the above functions, NOX has been shown to play a crucial role in chronic CNS diseases like Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and in acute CNS disorders such as stroke, spinal cord injury, traumatic brain injury (TBI), and related cerebrovascular diseases. NOX is a multi-subunit complex consisting of two membrane-associated and four cytosolic subunits. Thus, in recent years, inhibition of NOX activity has drawn a great deal of attention from researchers in the field of treating chronic and acute CNS disorders and preventing secondary complications. Mounting evidence has shown that NOX inhibition is neuroprotective and that inhibiting NOX in circulating immune cells can improve neurological disease conditions. This review summarizes recent studies on the therapeutic effects and pharmacological strategies regarding NOX inhibitors in chronic and acute brain diseases and focuses on the hurdles that should be overcome before their clinical implementation.

AB - Oxidative stress is a key player in both chronic and acute brain disease due to the higher metabolic demand of the brain. Among the producers of free radicals, NADPH-oxidase (NOX) is a major contributor to oxidative stress in neurological disorders. In the brain, the superoxide produced by NOX is mainly found in leukocytes. However, recent studies have reported that it can be found in several other cell types. NOX has been reported to regulate neuronal signaling, memory processing, and central cardiovascular homeostasis. However, overproduction of NOX can contribute to neurotoxicity, CNS degeneration, and cardiovascular disorders. Regarding the above functions, NOX has been shown to play a crucial role in chronic CNS diseases like Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and in acute CNS disorders such as stroke, spinal cord injury, traumatic brain injury (TBI), and related cerebrovascular diseases. NOX is a multi-subunit complex consisting of two membrane-associated and four cytosolic subunits. Thus, in recent years, inhibition of NOX activity has drawn a great deal of attention from researchers in the field of treating chronic and acute CNS disorders and preventing secondary complications. Mounting evidence has shown that NOX inhibition is neuroprotective and that inhibiting NOX in circulating immune cells can improve neurological disease conditions. This review summarizes recent studies on the therapeutic effects and pharmacological strategies regarding NOX inhibitors in chronic and acute brain diseases and focuses on the hurdles that should be overcome before their clinical implementation.

UR - http://www.scopus.com/inward/record.url?scp=85070762783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070762783&partnerID=8YFLogxK

U2 - 10.1016/j.ibror.2019.07.1721

DO - 10.1016/j.ibror.2019.07.1721

M3 - Review article

AN - SCOPUS:85070762783

VL - 7

SP - 59

EP - 69

JO - IBRO Reports

JF - IBRO Reports

SN - 2451-8301

ER -